Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Liver Transplant
Interventions: arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus; Biological · Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy
Interventions: Vamorolone, Prednisone, Placebo; Drug · Other
Lead sponsor: ReveraGen BioPharma, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Davis, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Metastatic Breast Cancer
Interventions: Lifestyle Intervention, Attention Control; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Maywood, Illinois • Milwaukee, Wisconsin

Conditions: Healthy Lifestyle, Home Environment Related Disease, Child Behavior, Cognitive Change, Child Obesity, Parenting, Parents, Parent-Child Relations
Interventions: Healthy HomeStyles, Eat Healthy Be Active; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 110 Years
Enrollment: 247 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Gastrointestinal Dysmotility
Interventions: Ulimorelin Intravenously (IV), 5% dextrose in water; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more

Conditions: Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer
Interventions: MORAb-009; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Interventions: CD22CART cell infusion; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Delayed Post-Polypectomy Induced Ulcer Hemorrhage
Interventions: Doppler Endoscopic Probe; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Downey, California • Los Angeles, California • West Los Angeles, California

Conditions: Healthy Volunteers
Interventions: AEF0117 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: HIV
Interventions: Message Sidedness; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,031 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lateral Canthal Lines, Crow's Feet
Interventions: ANT-1207, Botulinum Toxin Type A; Biological
Lead sponsor: Anterios Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Miami Beach, Florida • West Palm Beach, Florida + 3 more

Conditions: Schizophrenia
Interventions: Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions; Other
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer Disease
Interventions: Bryostatin, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Fresno, California • Los Alamitos, California • Santa Ana, California + 23 more

Conditions: Borderline Personality Disorder
Interventions: Caplyta, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Episode, Bipolar 1 Depression
Interventions: SEP-4199 200 mg, SEP-4199 400 mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 4 more

Conditions: Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions: XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more

Conditions: Cancer
Interventions: EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate), 99mTC-EC20 (Folic acid-technetium 99m conjugate); Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Detroit, Michigan • Las Vegas, Nevada

Conditions: Sickle Cell Disease, Pain Management
Interventions: Hypnosis, Control; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Non Small Cell Lung Cancer
Interventions: DZD6008, Sunvozertinib; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: New York, New York • Fairfax, Virginia

Conditions: Pancreatic Neoplasm
Interventions: Ascorbate, Gemcitabine, radiation therapy; Drug · Radiation
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Influenza
Interventions: Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 427 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more

Conditions: Respiratory Tract Infections
Interventions: MeMed BV® biomarker test, Usual care; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions: IFx-Hu2.0; Biological
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Brandon, Florida

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: vandetanib and dasatinib; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Months to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Liver Transplantation With Tregs at MGH

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity in SNAP-Education

Ulimorelin Study of Efficacy and Safety (ULISES 007)

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

HIV Testing & Womens Attitudes on HIV Vaccine Trials

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

Creating Live Interactions to Mitigate Barriers

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

Caplyta in Borderline Personality Disorder

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Study of EC0225 for the Treatment of Refractory or Metastatic Tumors

Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)